Delivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage
Kaouthar Bouzinab, Helen S. Summers, Malcolm F. G. Stevens, Christopher J. Moody, Neil R. Thomas, Pavel Gershkovich, Nicola Weston, Marianne Ashford, Tracey D. Bradshaw, Lyudmila Turyanska
Abstract
-MeG repair conferred by MGMT. We have additionally encapsulated >500 molecules of the N3-propargyl imidazotetrazine analog (N3P), developed to combat TMZ resistance, and demonstrated significantly enhanced activity of AFt-N3P against GBM and colorectal carcinoma cell lines. These studies support the use of AFt as a promising nanodelivery system for targeted delivery, lysosomal drug release, and enhanced imidazotetrazine potency for treatment of GBM and wider-spectrum malignancies.
Topics & Concepts
TemozolomideCancer researchNanocagesChemosensitizerDacarbazinePharmacologyMaterials scienceCytotoxicityMedicineChemistryGliomaIn vitroBiochemistryCatalysisMelanomaAdvanced biosensing and bioanalysis techniquesRNA Interference and Gene DeliveryIron Metabolism and Disorders